A42867, a novel glycopeptide antibiotic

Area of Science:

• Microbiology
• Medicinal Chemistry
• Biochemistry

Background:

• Glycopeptide antibiotics, such as vancomycin, are crucial for treating Gram-positive bacterial infections.
• The emergence of antibiotic resistance necessitates the discovery of new antimicrobial agents.
• The ristocetin-vancomycin class represents a significant group of glycopeptide antibiotics.

Purpose of the Study:

• To discover and characterize novel glycopeptide antibiotics.
• To identify new members of the ristocetin-vancomycin class with potential therapeutic applications.
• To elucidate the structure and biological activity of the newly isolated compound A42867.

Main Methods:

• Screening for new glycopeptide antibiotics using an acyl-D-alanyl-D-alanine affinity probe.
• Isolation and purification of A42867 via affinity chromatography.
• Structural elucidation using fast atom bombardment mass spectrometry (MS), high-field 2D proton nuclear magnetic resonance (1H NMR) spectroscopy, and high-performance liquid chromatography (HPLC) analysis of hydrolyzed carbohydrates.

Main Results:

• A new glycopeptide antibiotic, designated A42867, was isolated from Nocardia nov. sp. ATCC 53492.
• The structure of A42867 was determined, revealing differences in the sugar moiety and a single chlorine atom in the peptide core compared to vancomycin.
• A42867 demonstrated biological activity against aerobic and anaerobic Gram-positive bacteria, comparable to other antibiotics in its class.

Conclusions:

• A42867 represents a new addition to the ristocetin-vancomycin class of glycopeptide antibiotics.
• Its distinct structural features and comparable biological activity suggest potential as a therapeutic agent against Gram-positive bacterial infections.
• Further research into A42867's efficacy and safety profile is warranted.